Kymera Therapeutics (KYMR) Stock Forecast, Price Target & Predictions


KYMR Stock Forecast


Kymera Therapeutics (KYMR) stock forecast, based on 13 Wall Street analysts, predicts a 12-month average price target of $58.25, with a high of $65.00 and a low of $55.00. This represents a 54.71% increase from the last price of $37.65.

$25 $33 $41 $49 $57 $65 High: $65 Avg: $58.25 Low: $55 Last Closed Price: $37.65

KYMR Stock Rating


Kymera Therapeutics stock's rating consensus is Buy, based on 13 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 7 Buy (53.85%), 6 Hold (46.15%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 13 6 7 0 Strong Sell Sell Hold Buy Strong Buy

KYMR Price Target Upside V Benchmarks


TypeNameUpside
StockKymera Therapeutics54.71%
SectorHealthcare Stocks 25.10%
IndustryBiotech Stocks 61.24%

Price Target Trends


1M3M12M
# Anlaysts-28
Avg Price Target-$56.00$55.88
Last Closing Price$37.65$37.65$37.65
Upside/Downside-48.74%48.42%
Ratings Trends

DateStrong BuyBuyHoldSellStrong SellTotal
Feb, 253134--20
Jan, 253134--20
Dec, 243134--20
Nov, 246114--21
Oct, 246106--22
Analyst Price Target Forecasts

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 05, 2024Etzer DaroutBMO Capital$55.00$44.0824.77%46.08%
Dec 02, 2024Derek ArchilaWells Fargo$57.00$48.5417.43%51.39%
Sep 27, 2024Jeff JonesOppenheimer$56.00$49.4713.20%48.74%
Aug 26, 2024Andy ChenWolfe Research$65.00$47.7836.04%72.64%
Aug 08, 2024Andrew FeinH.C. Wainwright$60.00$40.3148.85%59.36%
Jun 17, 2024Andrew FeinH.C. Wainwright$46.00$32.2942.46%22.18%
May 23, 2024Edward TenthoffPiper Sandler$56.00$34.8460.73%48.74%
May 03, 2024Jeff JonesOppenheimer$52.00$36.3043.25%38.11%
Jan 03, 2023Wells Fargo$42.00$24.7169.97%11.55%
Dec 19, 2022Morgan Stanley$41.00$27.0551.57%8.90%
Analyst Rating Forecasts

DateCompanyPrevious RatingNew RatingRating Change
Dec 05, 2024BMO CapitalMarket Performinitialise
Oct 31, 2024JefferiesBuyBuyhold
Sep 27, 2024Wolfe ResearchEqual-WeightEqual-Weighthold
Sep 27, 2024OppenheimerOutperformOutperformhold
Sep 09, 2024Wolfe ResearchBuyBuyhold
Aug 26, 2024Wolfe ResearchOutperformupgrade
Aug 14, 2024Morgan StanleyEqual-WeightEqual-Weighthold
Aug 12, 2024Wells FargoBuyBuyhold
Aug 12, 2024Wells FargoEqual-WeightEqual-Weighthold
Aug 08, 2024H.C. WainwrightBuyBuyhold

Financial Forecast


EPS Forecast

$-9 $-8 $-7 $-6 $-5 $-4 $-3 $-2 $-1 $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.53$-2.04$-2.82------
Avg Forecast$-1.44$-1.86$-2.90$-2.64$-2.82$-3.06$-3.54$-3.57$-2.90
High Forecast$-0.44$-0.57$-0.64$-1.81$-2.15$-1.42$-2.49$-2.30$-0.03
Low Forecast$-3.18$-4.13$-7.72$-3.11$-3.15$-4.14$-5.73$-4.68$-8.26
Surprise %75.69%9.68%-2.76%------

Revenue Forecast

$0 $90M $180M $270M $360M $450M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$34.03M$72.83M$46.83M$78.59M-----
Avg Forecast$42.01M$83.71M$50.19M$69.37M$53.87M$68.16M$63.62M$88.05M$181.58M
High Forecast$81.32M$162.04M$114.40M$118.35M$107.40M$170.65M$64.51M$89.94M$439.66M
Low Forecast$19.65M$39.15M$20.17M$39.77M$42.96M$18.28M$62.72M$86.16M$43.53M
Surprise %-18.99%-12.99%-6.70%13.30%-----

Net Income Forecast

$-500M $-400M $-300M $-200M $-100M $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-43.95M$-98.00M$-151.83M$-146.96M-----
Avg Forecast$-83.85M$-78.75M$-127.85M$-146.96M$-167.47M$-162.27M$-319.20M$-203.93M$-169.39M
High Forecast$-25.83M$-63.00M$-102.28M$-117.57M$-125.71M$-83.08M$-145.22M$-134.43M$-1.97M
Low Forecast$-185.85M$-94.50M$-153.42M$-176.35M$-184.14M$-241.47M$-334.37M$-273.43M$-482.36M
Surprise %-47.59%24.43%18.76%------

KYMR Forecast FAQ


Is Kymera Therapeutics stock a buy?

Kymera Therapeutics stock has a consensus rating of Buy, based on 13 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 7 Buy, 6 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Kymera Therapeutics is a favorable investment for most analysts.

What is Kymera Therapeutics's price target?

Kymera Therapeutics's price target, set by 13 Wall Street analysts, averages $58.25 over the next 12 months. The price target range spans from $55 at the low end to $65 at the high end, suggesting a potential 54.71% change from the previous closing price of $37.65.

How does Kymera Therapeutics stock forecast compare to its benchmarks?

Kymera Therapeutics's stock forecast shows a 54.71% upside, outperforming the average forecast for the healthcare stocks sector (25.10%) and underperforming the biotech stocks industry (61.24%).

What is the breakdown of analyst ratings for Kymera Therapeutics over the past three months?

  • February 2025: 15.00% Strong Buy, 65.00% Buy, 20.00% Hold, 0% Sell, 0% Strong Sell.
  • January 2025: 15.00% Strong Buy, 65.00% Buy, 20.00% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 15.00% Strong Buy, 65.00% Buy, 20.00% Hold, 0% Sell, 0% Strong Sell.

What is Kymera Therapeutics’s EPS forecast?

Kymera Therapeutics's average annual EPS forecast for its fiscal year ending in December 2024 is $-2.82, marking a 0% decrease from the reported $0 in 2023. Estimates for the following years are $-3.06 in 2025, $-3.54 in 2026, $-3.57 in 2027, and $-2.9 in 2028.

What is Kymera Therapeutics’s revenue forecast?

Kymera Therapeutics's average annual revenue forecast for its fiscal year ending in December 2024 is $53.87M, reflecting a -31.45% decrease from the reported $78.59M in 2023. The forecast for 2025 is $68.16M, followed by $63.62M for 2026, $88.05M for 2027, and $181.58M for 2028.

What is Kymera Therapeutics’s net income forecast?

Kymera Therapeutics's net income forecast for the fiscal year ending in December 2024 stands at $-167M, representing an 13.96% increase from the reported $-147M in 2023. Projections indicate $-162M in 2025, $-319M in 2026, $-204M in 2027, and $-169M in 2028.